Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 70.48 USD 0.14% Market Closed
Market Cap: 41.6B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Gross Margin
Edwards Lifesciences Corp

78.6%
Current
78%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.6%
=
Gross Profit
4.4B
/
Revenue
5.6B

Gross Margin Across Competitors

Country US
Market Cap 41.6B USD
Gross Margin
79%
Country US
Market Cap 204.9B USD
Gross Margin
56%
Country US
Market Cap 195.2B USD
Gross Margin
67%
Country US
Market Cap 146.7B USD
Gross Margin
64%
Country US
Market Cap 132.6B USD
Gross Margin
69%
Country IE
Market Cap 110.6B USD
Gross Margin
66%
Country US
Market Cap 64.7B USD
Gross Margin
45%
Country DE
Market Cap 55.6B EUR
Gross Margin
38%
Country CN
Market Cap 319.2B CNY
Gross Margin
65%
Country US
Market Cap 37.7B USD
Gross Margin
41%
Country US
Market Cap 35.8B USD
Gross Margin
58%
No Stocks Found

Edwards Lifesciences Corp
Glance View

Market Cap
41.6B USD
Industry
Health Care

Edwards Lifesciences Corp., a leader in heart valve technologies and hemodynamic monitoring, has carved out a vital niche in the medical device industry. Founded in 1958 and based in Irvine, California, the company has consistently focused on innovative solutions to treat advanced cardiovascular diseases. Its flagship product, the transcatheter aortic valve replacement (TAVR), revolutionized how patients with severe aortic stenosis are treated, allowing doctors to perform minimally invasive procedures that significantly improve patient outcomes. As the global population ages and cardiovascular diseases become increasingly prevalent, Edwards is well-positioned to capitalize on this growing demand, with a robust pipeline of products aimed at addressing unmet medical needs. For investors, Edwards Lifesciences represents a compelling opportunity to tap into the expanding medical technology market. The company's strong financial performance, characterized by consistent revenue growth and impressive profit margins, highlights its effective execution and market leadership. Moreover, Edwards is committed to innovation, investing heavily in research and development, which not only fuels new product launches but also enhances its competitive edge. With a focus on long-term growth, expanding market presence, and a dedication to improving patient care, Edwards Lifesciences stands out as a promising investment for those looking to gain exposure to the dynamic healthcare sector.

EW Intrinsic Value
54.97 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.6%
=
Gross Profit
4.4B
/
Revenue
5.6B
What is the Gross Margin of Edwards Lifesciences Corp?

Based on Edwards Lifesciences Corp's most recent financial statements, the company has Gross Margin of 78.6%.